Methyldopa tablet how supplied storage and handling: Difference between revisions
(Created page with "__NOTOC__ {{Methyldopa}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = h...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==HOW SUPPLIED:== | |||
Methyldopa Tablets, USP are supplied as film-coated tablets containing either 250 mg or 500 mg of Methyldopa, USP. | |||
The 250 mg tablets are beige, film-coated, round, unscored tablets debossed with MYLAN on one side of the tablet and 611 on the other side. They are available as follows: | |||
NDC 51079-200-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each). | |||
The 500 mg tablets are beige, film-coated, capsule-shaped, unscored tablets debossed with MYLAN on one side of the tablet and 421 on the other side. They are available as follows: | |||
NDC 51079-201-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each). | |||
Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] | |||
Protect from light. | |||
Manufactured by: | |||
Mylan Pharmaceuticals Inc. | |||
Morgantown, WV 26505 | |||
Packaged and Distributed by: | |||
UDL Laboratories, Inc. | |||
Rockford, IL 61103 | |||
S-9014 R2 | |||
1/07<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87d63fd-48f7-4130-af03-5e263c338fe4 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 16:09, 10 March 2014
| Methyldopa |
|---|
| Methyldopa tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Methyldopa injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Methyldopa |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
HOW SUPPLIED:
Methyldopa Tablets, USP are supplied as film-coated tablets containing either 250 mg or 500 mg of Methyldopa, USP.
The 250 mg tablets are beige, film-coated, round, unscored tablets debossed with MYLAN on one side of the tablet and 611 on the other side. They are available as follows:
NDC 51079-200-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each).
The 500 mg tablets are beige, film-coated, capsule-shaped, unscored tablets debossed with MYLAN on one side of the tablet and 421 on the other side. They are available as follows:
NDC 51079-201-20 - Unit dose blister packages of 100 (10 cards of 10 tablets each).
Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from light.
Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV 26505
Packaged and Distributed by: UDL Laboratories, Inc. Rockford, IL 61103
S-9014 R2 1/07[1]
References
- ↑ "METHYLDOPA TABLET [CARDINAL HEALTH]". Retrieved 10 March 2014.